Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue in Severe Septic Shock
NCT06481410Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of methylene blue in septic shock (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: 28-day survival rate. Started Jun 2024; status: recruiting.
02
Drugs
methylene blue
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT06481410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481410.